#patients over profit ; new amsterdam | Explore Tumblr Posts and Blogs

jcmarchi · 3 months

Text

SoftBank launches healthcare venture with Tempus AI

New Post has been published on https://thedigitalinsider.com/softbank-launches-healthcare-venture-with-tempus-ai/

SoftBank launches healthcare venture with Tempus AI

.pp-multiple-authors-boxes-wrapper display:none; img width:100%;

SoftBank Group, the Japanese technology investment firm, has announced a strategic joint venture with Tempus AI, a company specialising in AI-driven medical data analysis and treatment recommendations.

This partnership was revealed by SoftBank’s CEO, Masayoshi Son, during a briefing in Tokyo, marking another significant move in SoftBank’s recent series of AI investments as the company ramps up its investment activities following a period of relative quiet.

Earlier this year, SoftBank invested approximately $200 million in Tempus during its Series G funding round, preceding Tempus’s Nasdaq listing in June. Tempus is renowned for its genomic testing services and AI-powered treatment and clinical trial recommendations in the United States, leveraging a comprehensive database of millions of patient clinical records.

As reported by Reuters, the partnership is hoped to enable these advanced services to be deployed in Japan, making it one of the first non-US healthcare markets with this type of connected health capabilities.

“Working with Tempus, we’ll develop services at pace in Japan. With the database of 7.7 million U.S. patients, we’re at a running start,” Son said about the venture.

The partnership is anticipated to close in July, subject to usual closing conditions, and will involve an investment of 15 billion yen (close to $93 million) from each party.

Google’s support for Tempus AI

Tempus AI has also recently caught the eye of Google, an Alphabet company that is still on a spending spree to acquire and develop artificial intelligence technologies. Google’s support is crucial for Tempus, as the search giant has been a major player in deploying AI over time. This includes standout systems like AlphaGo and foundational innovations such as the transformer architecture used in ChatGPT.

Tempus uses AI technology to develop what it describes as “intelligent diagnostics,” which are diagnostic tests tailored specifically to the patients they apply to. The initiative is designed to improve the efficacy of existing treatments and speed up the development of new therapies.

On June 14, 2024, Tempus conducted its IPO on the Nasdaq stock exchange. The company’s stock fared well, surging as much as 15% during its first day of trading and closing nearly 9 per cent higher. The market capitalisation of Tempus AI reached $6 billion.

Google’s financial involvement with Tempus AI began in June 2020 when Tempus issued a $330 million convertible promissory note to Google as part of a cloud services agreement. Later that year, Tempus provided Google with $80 million of preferred stock to partially satisfy the original note.

Over the period from 2002 to 2023, revenue at Tempus AI grew by 183%. Its adjusted earnings before interest, taxes, depreciation, and amortisation are improving, although it has yet to reach profitability.

The quality of its technology is evident from the current client base. Tempus has worked with approximately 95% of the world’s top 20 publicly traded biopharma companies. In addition to its collaborations with over 200 pharmaceutical companies, Tempus is used in over half of U.S. academic medical centres and connects with over 7,000 physicians.

This partnership between SoftBank and Tempus AI, coupled with Tempus’s market lead and its continuous strategic partnerships with numerous tech giants, establishes it as a significant participant among companies addressing new AI-powered healthcare services.

(Photo by Piron Guillaume)

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with other leading events including Intelligent Automation Conference, BlockX, Digital Transformation Week, and Cyber Security & Cloud Expo.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

Tags: ai, Google, healthcare ai

0 notes

phroyd · 4 years

Link

Delta Air Lines was hoping to restart flights next month from New York to Athens and Lisbon, two popular summer destinations, but it will probably have to wait a little longer.

The European Union is planning to bar most Americans even as it welcomes travelers from more than a dozen other countries next week, dealing a blow to Delta and other airlines hoping to revive their business as travel across the Atlantic Ocean typically peaks.

International flights make up a minority of flights for U.S. airlines but are typically much more profitable than domestic ones. And flights to and from Europe are generally the most important. U.S. and European airlines had reduced the number of available seats on flights connecting the two markets by about 75 percent next month compared with last July, according to the aviation data provider OAG. A travel ban on Americans, which European Union officials confirmed on Friday, will probably lead to even deeper cuts.

“It’s a huge deal,” said John Grant, a senior analyst at OAG. “It is by far the jewel in the crown for many major airline networks, in terms of both revenue and profitability.”

Last year, flights across the Atlantic, to Europe and other destinations, accounted for about 17 percent of passenger revenue for United Airlines, or about $7.4 billion. Such flights generated about 15 percent of all passenger revenue for Delta, or $6.4 billion, and about 11 percent of passenger revenue, or $4.6 billion, for American Airlines. They were particularly important to United and Delta, generating a quarter of passenger profits last year, according to the Transportation Department.

Tens of millions of people flew between the United States and European Union countries in 2019. Many traveled for business to and from cities like New York, Los Angeles and San Francisco and Amsterdam, London, Paris and Frankfurt. Many others fanned out farther to vacation, particularly in the summer, when international flights are often nearly full as American families jet off to Italy and Greece, and Europeans check out New York and California.

Of course, travel between the United States and the European Union has been restricted since March, when governments on both sides of the Atlantic barred most visitors to prevent the spread of the coronavirus, with exceptions for repatriations and “essential” travel by medical professionals.

At the time, the United States had just over 1,100 coronavirus cases as the virus spread extensively in Italy and Spain. Today, the United States leads the world with more than 2.4 million cases, and infections are surging in Arizona, California, Florida, Texas and other states. As a result, European Union officials have decided to keep Americans out — along with travelers from dozens of other countries — for fear that they could further spread the virus.

Because of the size of the United States, a vast majority of tickets sold by American carriers are for domestic travel. Those flights have led the industry’s recovery, as Americans slowly start to visit friends and family and make limited vacation plans, a pattern unfolding in countries around the world. Higher-profit business and international travel is expected to follow far behind.“I think international travel is probably going to lag domestic by up to 12 months,” Ed Bastian, Delta’s chief executive, told shareholders on a call last week, citing travel bans around the world as one reason.

The large difference in demand for domestic and international travel is also reflected in flight schedules. American, for example, plans to operate about 55 percent as many domestic flights next month as it did last July, but only about 20 percent as many international flights. The airline has delayed restarting service between the United States and a number of European destinations until August, a month later than planned.

The Coronavirus Outbreak

Frequently Asked Questions and Advice

Updated June 24, 2020

What’s the best material for a mask?

Scientists around the country have tried to identify everyday materials that do a good job of filtering microscopic particles. In recent tests, HEPA furnace filters scored high, as did vacuum cleaner bags, fabric similar to flannel pajamas and those of 600-count pillowcases. Other materials tested included layered coffee filters and scarves and bandannas. These scored lower, but still captured a small percentage of particles.

Is it harder to exercise while wearing a mask?

A commentary published this month on the website of the British Journal of Sports Medicine points out that covering your face during exercise “comes with issues of potential breathing restriction and discomfort” and requires “balancing benefits versus possible adverse events.” Masks do alter exercise, says Cedric X. Bryant, the president and chief science officer of the American Council on Exercise, a nonprofit organization that funds exercise research and certifies fitness professionals. “In my personal experience,” he says, “heart rates are higher at the same relative intensity when you wear a mask.” Some people also could experience lightheadedness during familiar workouts while masked, says Len Kravitz, a professor of exercise science at the University of New Mexico.

I’ve heard about a treatment called dexamethasone. Does it work?

The steroid, dexamethasone, is the first treatment shown to reduce mortality in severely ill patients, according to scientists in Britain. The drug appears to reduce inflammation caused by the immune system, protecting the tissues. In the study, dexamethasone reduced deaths of patients on ventilators by one-third, and deaths of patients on oxygen by one-fifth.

What is pandemic paid leave?

The coronavirus emergency relief package gives many American workers paid leave if they need to take time off because of the virus. It gives qualified workers two weeks of paid sick leave if they are ill, quarantined or seeking diagnosis or preventive care for coronavirus, or if they are caring for sick family members. It gives 12 weeks of paid leave to people caring for children whose schools are closed or whose child care provider is unavailable because of the coronavirus. It is the first time the United States has had widespread federally mandated paid leave, and includes people who don’t typically get such benefits, like part-time and gig economy workers. But the measure excludes at least half of private-sector workers, including those at the country’s largest employers, and gives small employers significant leeway to deny leave.

Does asymptomatic transmission of Covid-19 happen?

So far, the evidence seems to show it does. A widely cited paper published in April suggests that people are most infectious about two days before the onset of coronavirus symptoms and estimated that 44 percent of new infections were a result of transmission from people who were not yet showing symptoms. Recently, a top expert at the World Health Organization stated that transmission of the coronavirus by people who did not have symptoms was “very rare,” but she later walked back that statement.

What’s the risk of catching coronavirus from a surface?

Touching contaminated objects and then infecting ourselves with the germs is not typically how the virus spreads. But it can happen. A number of studies of flu, rhinovirus, coronavirus and other microbes have shown that respiratory illnesses, including the new coronavirus, can spread by touching contaminated surfaces, particularly in places like day care centers, offices and hospitals. But a long chain of events has to happen for the disease to spread that way. The best way to protect yourself from coronavirus — whether it’s surface transmission or close human contact — is still social distancing, washing your hands, not touching your face and wearing masks.

How does blood type influence coronavirus?

A study by European scientists is the first to document a strong statistical link between genetic variations and Covid-19, the illness caused by the coronavirus. Having Type A blood was linked to a 50 percent increase in the likelihood that a patient would need to get oxygen or to go on a ventilator, according to the new study.

How many people have lost their jobs due to coronavirus in the U.S.?

The unemployment rate fell to 13.3 percent in May, the Labor Department said on June 5, an unexpected improvement in the nation’s job market as hiring rebounded faster than economists expected. Economists had forecast the unemployment rate to increase to as much as 20 percent, after it hit 14.7 percent in April, which was the highest since the government began keeping official statistics after World War II. But the unemployment rate dipped instead, with employers adding 2.5 million jobs, after more than 20 million jobs were lost in April.

What are the symptoms of coronavirus?

Common symptoms include fever, a dry cough, fatigue and difficulty breathing or shortness of breath. Some of these symptoms overlap with those of the flu, making detection difficult, but runny noses and stuffy sinuses are less common. The C.D.C. has also added chills, muscle pain, sore throat, headache and a new loss of the sense of taste or smell as symptoms to look out for. Most people fall ill five to seven days after exposure, but symptoms may appear in as few as two days or as many as 14 days.

How can I protect myself while flying?

If air travel is unavoidable, there are some steps you can take to protect yourself. Most important: Wash your hands often, and stop touching your face. If possible, choose a window seat. A study from Emory University found that during flu season, the safest place to sit on a plane is by a window, as people sitting in window seats had less contact with potentially sick people. Disinfect hard surfaces. When you get to your seat and your hands are clean, use disinfecting wipes to clean the hard surfaces at your seat like the head and arm rest, the seatbelt buckle, the remote, screen, seat back pocket and the tray table. If the seat is hard and nonporous or leather or pleather, you can wipe that down, too. (Using wipes on upholstered seats could lead to a wet seat and spreading of germs rather than killing them.)

What should I do if I feel sick?

If you’ve been exposed to the coronavirus or think you have, and have a fever or symptoms like a cough or difficulty breathing, call a doctor. They should give you advice on whether you should be tested, how to get tested, and how to seek medical treatment without potentially infecting or exposing others.

“Demand is increasing, but those numbers, while they’re increasing, are still a fraction of what they were last year, particularly internationally,” Doug Parker, American’s chief executive, told shareholders this month.

The International Air Transport Association called on governments this week to avoid quarantine measures that can discourage travel in favor of less severe measures, like asking sick passengers to stay home and increasing testing.

After dropping to record lows in April, the number of people going through U.S. airport checkpoints is up to about 20 percent of last year’s levels, according to the Transportation Security Administration. That’s not nearly enough to sustain the nation’s largest airlines, which are losing tens of millions of dollars every day, but it has restored a sense of vitality to an industry ravaged by the pandemic.

And while international travel could remain subdued for months, airlines have found other ways to drive revenue, including operating cargo-only flights, which are in high demand.

“That’s going to stay in place until passenger demand starts to recover,” Scott Kirby, United’s chief executive, said at an investor conference last month. “So there’s an international hedge that cargo is going to stay strong until passenger demand recovers, and then passenger demand will take over for it.”

#united states #eu #travel #covid

9 notes · View notes

world-of-ryan · 4 years

Link

Imagine the hospital of all our dreams…. its heroic doctors and nurses go to extreme measures to help all patients. no one is turned away, and the impoverished receive the best care, with dignity.

Now, imagine no longer. That hospital is New Amsterdam. Modeled after Manhattan's Bellevue, the country's first public hospital, it is at the center of the NBC drama series New Amsterdam.

Bellevue also houses a jail, a school and a psych ward, and the writer-producers of the series draw from all those settings for their topical stories.

Due to the coronavirus, New Amsterdam had an abbreviated second season. Even so, some 45 million viewers tuned in, landing it in the top 20 network shows.

Now — as a nation anxiously watches nightly statistics of new infections, ICU bed count and ventilator usage — the series heads into its season three, with an additional two-year commitment.

"We certainly had no foresight we would be arriving in this moment, with a pandemic," says executive producer–director Peter Horton, reflecting on life before Covid-19. "But having a show that is predictable and comforting may be what people need and want."

That predictability and comfort stem from knowing the harried doctors are good people determined to do good. While New Amsterdam provides solace, it also tackles hot-button issues, including opioid addiction, immigration, poverty and racism.

Although a broadcast-network series is an unlikely platform for subversion — especially one that's oddly reassuring — that's what Horton wanted to achieve.

That's why he and fellow executive producer David Schulner, who is also creator and showrunner, weave in current events. (Also executive-producing are Michael Slovis, David Foster and Aaron Ginsburg.)

An episode in season one, "Cavitation," told of a police shooting of a Black and a Latino child and the subsequent death of one of them, despite the best efforts of the hospital staff.

Weaving a discussion of guns, policing and racial injustice into an hour-long entertainment series "is really tricky," Horton allows. "Network shows are not known for wanting to be controversial. But because it is in the context of a hospital show, of people wanting to do the right thing, we are able to tell that story and have it get out there and have its impact."

In the coming season — expected to start sometime this fall — the producers plan to take a hard look at the health effects of climate change. They're also rescheduling an eerily prescient episode, "Pandemic," about a killer flu in New York City.

It was postponed because its original April 7 airdate found New York City in the grip of Covid-19. While Horton calls that the right decision (after all, this series is about making the right decisions), he acknowledges it was difficult to yank what he considered one of the best episodes.

"The challenge for us and the network was: is this perfectly unplanned timing a gift from the gods, with New Amsterdam stepping in to say, 'It's going to be okay,' and doing what we do well?" Horton asks. "Or is this exploitive?"

That episode was supposed to introduce the series' newest doctor, Cassian Shin, played by Daniel Dae Kim.

In a scary example of life imitating art imitating life, Kim contracted the coronavirus during shooting. He has since recovered. Dr. Shin — "this great cowboy of a surgeon," as Horton describes him — joins the ensemble cast, which is led by Ryan Eggold as Max Goodwin, the hospital's medical director.

Goodwin is the physician everyone wants. Despite shortages of time, staff and funds, he always puts patients first, taking on hospital administrators and insurance companies. As Eggold explains, "Max is willing to break the rules to get someone cared for."

Indeed, if Goodwin's signature line, "How can I help?" were the trigger for a drinking game, viewers would be tipsy by the end of each hour.

In the real world, the doctor's aggressively unorthodox style might not be received so benignly, but he remains a force for good.

Meanwhile, Eggold's laid-back manner belies the character's own life experience, which sounds like the makings of a country song. The doctor was recently widowed, fought cancer and has a newborn to care for, while his job is a daily reminder of the world's ills.

Though its plots and characters are fictional, the show strives for accuracy. Some scenes are shot in Bellevue's striking atrium, designed by famed architect I.M. Pei. Real Bellevue physicians have spent time with their TV counterparts, and some even appear onscreen as extras.

Like its TV doppelgänger, Bellevue stands as testament to a society that cares for all.

It dates to the 1660s, when it was an infirmary for soldiers in a city then called New Amsterdam. The hospital moved to its current location on the East Side of Manhattan in the 1790s. Plagues that ravaged New York over the centuries — scarlet fever, the 1918 flu, AIDS and now coronavirus — have all filled its beds.

The show's inspiration was Twelve Patients: Life and Death at Bellevue Hospital, the 2012 memoir by Dr. Eric Manheimer, who was medical director of Bellevue for 15 years. To understand him and the show, you need only consider this paragraph:

"How people die and how we participate in their deaths is as much about us as about them. Our own humanity is at stake. In a society that is increasingly mesmerized by efficiency, measurement by numbers, and a bottom-line mentality that extols profit and wealth over any other human value, the risk is clear to everyone I work with. When healthcare is now measured by 'medical loss ratio,' and the percentage of spending on healthcare is considered a 'loss,' then we are really lost."

Schulner brought Manheimer's memoir to Universal Television in 2016 when, he notes, all conversations revolved around immigration and health care.

"I thought, 'Why would I want to write about anything else?'" he recalls. "These conversations were passionate and angry and full of personal anecdotes and personal connections. The one thing missing was a sense of hope.

"Everyone agreed the health care system was broken, and no one had hope we could get out of it. I wanted to write about that."

Worried that the medical chief might seem saintly, Schulner made sure that among Goodwin's foibles is an inability to devote energy to his own life. "Max can't give anyone 100 percent except, of course, his patients," Schulner says. ...

For the rest of the story, pick up a copy of the latest issue of emmy magazine HERE

This article originally appeared in its entirety in emmy magazine, Issue No. 8, 2020

#new amsterdam #freema agyeman #jocko sims #janet montgomery #ryan eggold #anupam kher #tyler labine

3 notes · View notes

momo9727 · 6 years

Text

passion.

So I’m watching New Amsterdam and I’m only two episodes in but I’ve felt so many emotions already. I want nothing more out of life than to be a medical professional that dedicates their life to helping others and I’m currently working towards that but even so, I know that it may not be all its cracked up to be. The medical field has become such a monetary industry that goals are being improperly aligned and the priority has shifted from patients to title and profit. I love that this show exploits it all- the HAIs, the unnecessary procedures, the over prescription of medication, and so forth. Being a doctor is solely about helping improve the lives of others and you have to want it more than anything. If you have any other motive or intention then change careers because this is not for you. Its unfortunate that medicine in terms of the field has become a “quick fix” industry rather than one that focuses on treating the patient and instead on treating their symptoms. Reform is needed and I appreciate the direction of this show thus far.

#dailythoughts

1 note · View note

pharmaphorumuk · 4 years

Text

Sanofi to acquire Kiadis and NK cell tech for $353 million

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million).

The French pharma is buying Kiadis for 5.45 euros per share in cash, an offer price representing a premium of 272% over the biotech’s closing price on Friday evening on Amsterdam’s Euronext market.

It’s a substantial price to pay for the small pharma. Although the company’s share price has been notoriously volatile, the NK-cell technology is still largely unproven in clinic.

Allogeneic, or ‘off the shelf’, cell therapies are derived from banks of cells, and potentially offer the therapeutic benefits seen with autologous cell therapies derived from a patient’s own bodies but without the complex, costly and lengthy manufacturing process.

Autologous CAR-T cancer therapies based on T-cells are already on the market from Novartis and Gilead, but have had a slow start in terms of sales as health systems struggled to come to terms with their high price and the logistics of manufacturing them and delivering them to patients.

While Kiadis’ technology is mainly intended for cancer, the biotech announced plans in August to develop a NK-cell therapy for COVID-19, sending its shares soaring before they fell back due to profit-taking.

This followed a separate deal with Sanofi in July, where the pharma licensed Kiadis’ pre-clinical drug K-NK004 for multiple myeloma.

Kiadis has K-NK002 in phase 2 development to prevent patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes from relapsing after transplant.

Also in phase 1 development is K-NK003, for patients with relapsed or refractory AML.

Kiadis is drawing up plans to begin a phase 1/2a clinical trial of KNK-ID-101, its COVID-19 therapy in high risk patients, with funding from the French government.

Acquiring Kiadis outright makes sense for Sanofi, which already has a foothold in cancer immunotherapy thanks to its Libtayo (cemiplimab), developed in partnership with Regeneron and already approved in a form of skin cancer.

Shareholders in Kiadis will likely be pleased with the substantial premium agreed and the deal has the unanimous support of its board.

Funds managed by Life Sciences Partners have committed to support the offer, accounting for 18.3% of shares in the Netherlands-based biotech.

The post Sanofi to acquire Kiadis and NK cell tech for $353 million appeared first on .

from https://pharmaphorum.com/news/sanofi-to-acquire-kiadis-and-nk-cell-tech-for-353-million/

0 notes

selfmadesaviour · 2 years

Text

tag drop.

#fulfilled expectations ; cm #just like home ; cpd #especially heinous ; svu #two equally important parts ; law and order #code red ; grey's #we all do what we can ; the resident #patients over profit ; new amsterdam #rabid dogs are put down ; hannibal #as long as i have you ; season four #i will always find you ; ghost #from now until forever ; stabler teens #not the other shepherd ; new amsterdam #two sides of the same coin ; new amsterdam #a fresh start ; med #something about this town ; chicago #i need to get away ; new york #communication is vital ; gaffney #need a new start ; the rookie

1 note · View note

mdye · 7 years

Link

President Donald Trump’s pick for head of the U.S. Department of Health and Human Services’ Office for Civil Rights will lead a division that is supposed to crack down on discrimination—and has a lengthy anti-LGBT record.

Roger Severino, a former lawyer with the Becket Fund, a law firm that advocates for religious liberty, was one of the leading attorneys in the 2006 Conaway v. Deane case, banning same-sex couples from marriage in Maryland. In August 2006, Severino penned an op-ed for the Philadelphia Inquirer saying that the concept “live and let live” doesn’t apply to gay rights and religious beliefs.

That was about a month before Severino and Anthony R. Picarello, a former colleague and now vice president and general counsel of the Becket Fund, filed a brief with the Maryland Court of Appeals that used religion as a basis to reject health benefits to same-sex partners (PDF).

The case involved an effort by nine Maryland couples to win marriage rights in the state. According to the brief, Severino and his partner filed, “If legalized same-sex marriage becomes more common, employees will likely ask their religious employers to extend spousal health and retirement benefits to those partners, just as they would to different sex spouses. Some religious employers may be willing to overlook or ignore an employee’s same-sex marriage, but may also refuse to subsidize it, or otherwise treat it as the equivalent of traditional marriage on religious grounds.”

The brief continued: “Legalized same-sex marriage will create an unprecedented level of legal confusion and consequent litigation in public accommodation and employment law, and over government funding with the only certainty being that they will challenge the workings of religious institutions like never before.” And it asked: “Will state governments force religious institutions to place orphan children under their care within same-sex ‘families’?”

Severino has just assumed leadership of the Office for Civil Rights at HHS, he will oversee and enforce patient privacy protections and defend the public against discrimination in health care, according to the Office for Civil Rights website.

During the Obama era, the Office for Civil Rights implemented section 1557 in the Affordable Care Act (ACA), which protected transgender individuals based on gender identity and prohibited religious exemption. Given Servino’s anti-LGBT record, he might reverse these protections. He has written scathing critiques about the ACA’s new gender mandates, while also safe-guarding doctors that use religion as a defense to neglect transgender patients.

Before his current post, Severino worked as the director of the DeVos Center for Religion and Civil Society at the Heritage Foundation, a research tank that analyzes the impact of religion on civic life and public policy in the United States.

“Roger Severino has a distinguished record of fighting for the civil rights and freedoms of all Americans. We have no doubt that Roger in his role at HHS will protect the civil rights of all Americans,” said Marguerite Bowling, a spokeswoman for Heritage.

Neither the Becket Fund nor HHS responded to direct requests for comment. A spokesperson for Becket said he couldn’t find an attorney to comment before press time for The Daily Beast’s emailed questions. However, in a statement sent to The Daily Beast, Eric Rassbach, deputy general counsel at Becket, said Severino worked “tirelessly to defend civil rights for all Americans in accordance with Becket’s mission of defending religious liberty for people of all faiths. He will be an outstanding director of the Office of Civil Rights.”

For nearly seven years, Severino worked as a trial attorney for the Department of Justice’s Civil Rights Division where he enforced the Fair Housing Act, the Religious Land Use and Institutionalized Persons Act, and Title II and Title VI of the Civil Rights Act of 1964, according to his HHS bio.

Advocacy groups with knowledge of Servino’s past have mixed views on his appointment.

Thank You!

You are now subscribed to the Daily Digest and Cheat Sheet. We will not share your email with anyone for any reason.

More than 10 years ago, Lambda Legal, a legal group defending LGBT communities, was a plaintiff on the Conaway case. In 2006, Lambda defended nine same-sex couples, including one gay widower, who sued the state of Maryland after being denied marriage licenses. Lambda lost the case.

Sharon McGowan, the director of strategy at Lambda, said she isn’t “optimistic” about Servino’s new role at HHS. “The arguments put forth by Severino and others at the Becket Fund during the marriage struggle were indicative of the scare tactics folks were trying to use to somehow pit equality for LGBT people against religion,” McGowan said. “The attempt of Roger Severino to suggest that religious liberty will come to an end if LGBT people are given equal rights under law… certainly, gives insight on where he would strike a balance if he were given the opportunity, that he has now been given to make civil rights laws.”

The National Center for Lesbian Rights (NCLR), a non-profit law firm advocating for LGBT constituents, said that Severino’s designation to the HHS is “deeply concerning” to the LGBT community.

“It’s a continuation of President Trump’s pattern of appointing people to lead important federal agencies who fundamentally disagree with the agencies’ mission,” said NCLR’s director of policy, Julianna Gonen. “Severino was a very vocal critic of the most important rules that he’s supposed to enforce which is prohibiting sex discrimination in health care under the affordable care act.”

In a blog post Severino co-wrote for Heritage, he complained that the Affordable Care Act’s gender identity mandate will interfere with the religious beliefs of doctors. “These regulations propose to penalize medical professionals and healthcare organizations that, as a matter of faith, moral conviction, or professional medical judgment, believe that maleness and femaleness are biological realities to be respected and affirmed, not altered or treated as diseases,” the post said.

Severino has even used the anti-LGBT vision of a local Boy Scouts chapter to object to gay rights. In an op-ed for the Philadelphia Inquirer, Severino spoke up for a Boy Scouts branch in Philadelphia that lost government-affiliated campsites and buildings after excluding LGBT students. In January, the Boy Scouts reversed rules that banned transgender members.

“If the gay-rights movement is willing to trample on the moral beliefs of the Boy Scouts for the sake of `tolerance,’ will religious institutions that also provide social services and oppose gay rights on religious grounds fare any better?” wrote Severino for the Philadelphia Inquirer in 2006.

In January, the Boy Scouts of America reversed rules that banned transgender members.

Tatyana Bellamy-Walker covers LGBT politics. Her work has appeared in the New York Daily News, New York Amsterdam News and Women’s eNews. She tweets at @bell_tati.

1 note · View note

congressplanners-blog · 4 years

Text

ESC 2020 - ESC Congress 2020 Annual Meeting

Attend the ESC 2020 annual congress that is being organized in Amsterdam – Netherlands. The congress meeting of European Society of Cardiology has scheduled the scientific sessions from Saturday 29 August to Wednesday 02 September 2020.

The meeting welcomes all medical professionals to meet at the Noord Holland, where the health care practitioners will meet here to examine cardiology and cardiovascular disease information. The ESC congress 2020 has arranged some of the expert sessions with approx. 33,000 and more participants, discussing the cardiology subjects with about all the attendees and exhibitors.

The Congress Program Panel will organize the new cardiovascular research and advancement where there will be over 500 sessions and 4,500 presentations for such a world-renowned professorship/

Being a part of this ESC 2020, you can attend and examine the Late-Breaking Science Sessions, Case-Based Sessions, Guidelines Presentations, and two fast-growing favourites. The 2020 Annual Meeting of the European Cardiology Society provides an excellent opportunity to exchange insights and develop information with cardiovascular practitioners so they can provide their patients with safer medical arrangements. This ESC congress 2020 annual meet engages in the academic sessions and lectures for the delegates along with the member National Cardiac Societies and -speciality groups of ESC. With the advanced medical procedures, treatment and control of heart and blood vessel disorders, several more subjects will be discussed in the presence of ESC fellows and individual members from around the world.

Understanding the ESC 2020 Congress meet

The European Cardiology Society is a non-profit medical society which works to create a better medical facility. Talking about the aim and focus the meet brings an outstanding platform for all the delegates and worldwide medical professionals. The ESC Congress 2020 focus theme is 'The Cutting Edge of Cardiology,' that includes unique sessions on the new technologies available today and on the horizon of clinical cardiology. Congress offers an opportunity to inspire, over and above its commitment to excellence in science and education. This is first and foremost an unlike any other celebration of exploration. The ultimate goal is to broaden the bounds of vascular pharmaceuticals so that millions of more people can lead longer, healthier lives.

Being an independent, non-governmental professional society, the ESC congress 2020 is led by the volunteers and participants who will be part of this grand meeting. This congress will be governed by leaders, healthcare practitioners and decision-makers. High-run clinical and academic work and world-renowned experts who have been working on their widely sought-after opinions with their expertise and utmost experience, and the articles are frequently printed and referenced.

What this ESC CONGRESS 2020 annual meet brings?

This year the 2020 Annual Conference of the European Cardiology Society will be held at in Netherland inviting thousands of medical experts. The conference will be all about cardiovascular disease treatment, addressing the entire spectrum of cardiology. The abstracts will be introduced and discussed, there will be companies sharing their proposals and showing the advancement in technology. The meeting will encourage some high-quality healthcare tips with the large network, and form an atmosphere that is good for cardiovascular health.

The ESC congress 2020 highlight includes the new clinical cardiology technologies along with the use of innovative treatments, including stem cells and genes. Heading towards personalized medicine big data, artificial intelligence and wearable technology to reshape medical care delivery; and robots to bring remote treatment and remote interventional cardiology to patients across the world.

Understanding the aim and mission, ESC or the European Society of Cardiology is working towards the betterment of the health of society. The Cardiovascular disease in Europe is the major problem that is the largest killer, responsible for 4 million deaths per year that can count more than 47 per cent of all deaths. Therefore every step and meet focus in the advancement and prevention, treatment, and control of heart and blood vessel diseases.

The ESC disseminates evidence-based medical information to cardiovascular practitioners so they can look after their patients more effectively. Therefore the ESC CONGRESS 2020 annual meet is another step for enhancing the knowledge and skills for cardiovascular treatment.

Get Hotel Reservations for ESC 2020 with Medconn

ESC 2020, the world-famous congress meet that is inviting more than 33,000 worldwide delegates, that makes it one of the most important congresses for medical experts. Now, this can be a tougher task to book and arrange the needed.

With a great footfall getting ESC reservation can be a challenge, therefore Medconn is also working with ESC 2020 to reserve your seat along with Hotel Reservations. Meetings, airport transfers, shuttle services etc. Here the Medconn play their part in arranging for the best travel and Congress that includes Hotel Reservations for ESC 2020 and needs during your stay.

Have your cosy stay and well-arranged space for you and your party with registration for Congress, plans for pre- and post-congress meetings, meals, airport and congress transfers, and everything else your party asks for during the congress.

The areas covered by Medconn are the hotels, transitions with pre and post-congress arrangements. The team of Medconn have a list of the best 3-star to 5-star accommodation choice near the venue which is best in service stands. The Bed, Breakfast, Relevant Taxes and Wi-Fi are the choices you'll get when you book the service with Medconn. With the deep technical and business partnership network with reliable partners and suppliers, the service rendered by congress planners makes them the reliable side. Get your Hotel Reservations Near ESC 2020 Venue to reduce the distance of travel and save a lot of time.

Interested? Let's Get In Touch!

We would love to assist you regarding

ESC Congress 2020 | European Society of Cardiology

[email protected]

#ESC 2020 #ESC CONGRESS 2020 Annual Meeting #esc

0 notes

qwertsypage · 5 years

Text

RisingStack in 2019 - Achievements, Highlights and Blogposts.

🎄 How was 2019 at RisingStack? 🥳 - you might ask, as a kind reader already did it in a comment under our wrap-up of 2018.

Well, it was an intensive year with a lot of new challenges and major events in the life of our team!

Just to quickly sum it up:

We grew our team to 16! All of our engineers are full-stack in the sense that we can confidently handle front-end, back-end, and operations tasks as well - as you'll see from this year's blogpost collection.

We launched our new website, which communicates what we do and capable of more clearly (I hope at least). 🤞 Also, a new design for the blog is coming as well!

This year ~1.250.000 developers (unique users) visited our blog! 🤩

We just surpassed 5.7 million unique readers in total, who generated almost 12 million pageviews so far in the past 5 years.

We have now more than 220 articles on the site - written by our team exclusively.

We had the honor to participate in JSconf Budapest by providing a workshop for attendees on GraphQL and Apollo. 🎓

We delivered a 10-weeks-long online DevOps training for around 100 developers in partnership with HWSW, Hungary's leading tech newspaper.

We kept on organizing local Node.js meetups here in Budapest, with more than 100 attendees for almost every event this year. 🤓

We had the opportunity to work with huge companies like DHL, Canvas (market leader e-learning platform), and Uniqa (insurance corp.).

We met with fantastic people all over the world. We've been in LA, Sarajevo, Amsterdam, Prague, and Helsinki too. 🍻

We moved to a new office in the heart of Budapest!

🤔 Okay, okay... But what about blogging?

Blogging in 2019

You might have noticed that we did not write as much blogposts this year as we did before.

The reason is simple: Fortunately, we had so many new projects and clients that we had very little time to write about what we love and what we do.

Despite our shrinking time for writing blogposts, I think we still created interesting articles that you might learn a thing or two from.

Here's a quick recap from the blog in 2019. You can use this list to navigate.

Stripe 101 for JavaScript Developers

Generating PDF from HTML with Node & Puppeteer

REST in Peace. Long Live GraphQL!

Case Study: Nameserver Issue Investigation

RisingStack Joins the Cloud Native Node.js Project

A Definitive React-Native Guide for React Developers

Design Systems for React Developers

Node.js v12 - New Features You Shouldn't Miss

Building a D3.js Calendar Heatmap

Golang Tutorial for Node.js Developers

How to Deploy a Ceph Storage to Bare Virtual Machines

Update Now! Node.js 8 is Not Supported from 2020.

Great Content from JSConf Budapest 2019

Get Hooked on Classless React

Stripe 101 for JavaScript Developers

Sample app, detailed guidance & best practices to help you get started with Stripe Payments integration as a JavaScript developer.

At RisingStack, we’ve been working with a client from the US healthcare scene who hired us to create a large-scale webshop they can use to sell their products. During the creation of this Stripe based platform, we spent a lot of time with studying the documentation and figuring out the integration. Not because it is hard, but there's a certain amount of Stripe related knowledge that you'll need to internalize.

Read: Stripe Payments Integration 101 for JavaScript Developers

Generating PDF from HTML with Node & Puppeteer

Learn how you can generate a PDF document from a heavily styled React page using Node.js, Puppeteer, headless Chrome, and Docker.

Background: A few months ago, one of the clients of RisingStack asked us to develop a feature where the user would be able to request a React page in PDF format. That page is basically a report/result for patients with data visualization, containing a lot of SVGs. Furthermore, there were some special requests to manipulate the layout and make some rearrangements of the HTML elements. So the PDF should have different styling and additions compared to the original React page.

As the assignment was a bit more complex than what could have been solved with simple CSS rules, we first explored possible implementations. Essentially we found 3 main solutions we describe in this article.

Read: Generating PDF from HTML with Node.js and Puppeteer

REST in Peace. Long Live GraphQL!

As you might already hear about it, we're the organizers of the Node.js Budapest meetup group with around ~1500 members. During an event in February, Peter Czibik delivered a talk about GrahpQL to an audience of about 120 ppl.

It was a highly informative and fun talk, so I recommend you to check it out!

Case Study: Nameserver Issue Investigation

In the following blogpost, we will walk you through how we chased down a DNS resolution issue for one of our clients. Even though the problem at hand was very specific, you might find the steps we took during the investigation useful.

Also, the tools we used might also prove to be helpful in case you'd face something similar in the future. We will also discuss how the Domain Name System (works), so buckle up!

Read the blogpost here: Case Study: Nameserver Issue Investigation using curl, dig+trace & nslookup

RisingStack Joins the Cloud Native Node.js Project

In March 2019, we announced our collaboration with IBM on the Cloud Native JS project, which aims to provide best practices and tools to build and integrate enterprise-grade Cloud Native Node.js applications.

As a first step of contribution to the project, we released an article on CNJS’s blog - titled “How to Build and Deploy a Cloud Native Node.js App in 15 minutes”. In this article we show how you can turn a simple Hello World Node.js app into a Dockerized application running on Kubernetes with all the best-practices applied - using the tools provided by CNJS in the process.

A Definitive React-Native Guide for React Developers

In this series, we cover the basics of React-Native development, compare some ideas with React, and develop a game together. By the end of this tutorial, you’ll become confident with using the built-in components, styling, storing persisting data, animating the UI, and many more.

Part I: Getting Started with React Native - intro, key concepts & setting up our developer environment

Part II: Building our Home Screen - splitting index.js & styles.js, creating the app header, and so on..

Part III: Creating the Main Game Logic + Grid - creating multiple screens, type checking with prop-types, generating our flex grid

Part IV: Bottom Bar & Responsible Layout - also, making our game pausable and adding a way to lose!

Part V: Sound and Animation + persisting data with React-Native AsyncStorage

Design Systems for React Developers

In this post, we provide a brief introduction to design systems and describe the advantages and use-cases for having one. After that, we show Base Web, the React implementation of the Base Design System which helps you build accessible React applications super quickly.

Node.js v12 - New Features You Shouldn't Miss

Node 12 is in LTS since October, and will be maintained until 2022. Here is a list of changes we consider essential to highlight:

V8 updated to version 7.4

Async stack traces arrived

Faster async/await implementation

New JavaScript language features

Performance tweaks & improvements

Progress on Worker threads, N-API

Default HTTP parser switched to llhttp

New experimental “Diagnostic Reports” feature

Read our deep-dive into Node 12 here.

Building a D3.js Calendar Heatmap

In this article, we take a look at StackOverflow’s usage statistics by creating an interactive calendar heatmap using D3.js!

We go through the process of preparing the input data, creating the chart with D3.js, and doing some deductions based on the result.

Read the full article here Building a D3.js Calendar Heatmap. Also, this article has a previous installment called Building Interactive Bar Charts with JavaScript.

Golang Tutorial for Node.js Developers

In case you are a Node.js developer, (like we are at RisingStack) and you are interested in learning Golang, this blogpost is made for you! Throughout this tutorial series, we'll cover the basics of getting started with the Go language, while building an app and exposing it through a REST, GraphQL and GRPC API together.

In the first part of this golang tutorial series, we’re covering:

Golang Setup

net/http with Go

encoding/json

dependency management

build tooling

Read the Golang for Node developers tutorial here.

How to Deploy a Ceph Storage to Bare Virtual Machines

Ceph is a freely available storage platform that implements object storage on a single distributed computer cluster and provides interfaces for object-, block- and file-level storage. Ceph aims primarily for completely distributed operation without a single point of failure. It manages data replication and is generally quite fault-tolerant. As a result of its design, the system is both self-healing and self-managing.

Ceph has loads of benefits and great features, but the main drawback is that you have to host and manage it yourself. In this post, we're checking out two different approaches of deploying Ceph.

Read the article: Deploying Ceph to Bare Virtual Machines

Update Now! Node.js 8 is Not Supported from 2020.

The Node.js 8.x Maintenance LTS cycle will expire on December 31, 2019 - which means that Node 8 won’t get any more updates, bug fixes or security patches. In this article, we’ll discuss how and why you should move to newer, feature-packed, still supported versions.

We’re also going to pinpoint issues you might face during the migration, and potential steps you can take to ensure that everything goes well.

Read the article about updating Node here.

Great Content from JSConf Budapest 2019

JSConf Budapest is a JSConf family member 2-day non-profit community conference about JavaScript in the beautiful Budapest, Hungary. RisingStack participated in the conf for several years as well as we did this September.

In 2019 we delivered a workshop called "High-Performance Microservices with GraphQL and Apollo" as our contribution to the event.

We also collected content you should check out from the conf. Have fun!

Get Hooked on Classless React

Our last meetup in 2019 was centered around React Hooks. What is a hook?

A Hook is a function provided by React, which lets you hook into React features from your functional component. This is exactly what we need to use functional components instead of classes. Hooks will give you all React features without classes.

Hooks make your code more maintainable, they let you reuse stateful logic, and since you are reusing stateful logic, you can avoid the wrapper hull and the component reimplementation.

Check out the prezentation about React Hooks here.

RisingStack in 2020

We're looking forward to the new year with some interesting plans already lined up for Q1:

We'll keep on extending our team to serve new incoming business.

We have several blogposts series in the making, mainly on DevOps topics.

We'll announce an exciting new event we'll co-organize with partners from the US and Finnland soon, so stay tuned!

We're going to release new training agendas around Node, React & GraphQL, as well as a new training calendar with open trainings for 2020.

How was your 2019?

RisingStack in 2019 - Achievements, Highlights and Blogposts. published first on https://koresolpage.tumblr.com/

0 notes

cleopatrarps · 6 years

Text

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON (Reuters) – GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world’s leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

FILE PHOTO: Dolutegravir pills used in the treatment of HIV are seen at the Kenyan ministry of health offices in Nairobi, Kenya, June 27, 2017. Picture taken June 27, 2017. REUTERS/Baz Ratner

The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach.

Deborah Waterhouse, head of GSK’s majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.

She has her work cut out. Gilead currently has a market share of 52 percent against GSK’s 22 percent – a breakdown that has changed little this year, despite the successful launch of Gilead’s new three-drug medicine Biktarvy.

Last week GSK reported successful headline results with its experimental combination of dolutegravir and lamivudine, paving the way for potential approval next year of a therapy some analysts see selling $1.5 billion annually.

Details of its so-called GEMINI trials, however, will only be disclosed at the biennial International AIDS Conference in Amsterdam on July 24 – a day before GSK reports second-quarter results.

GSK was informed late last Friday that its presentation had been accepted at the meeting, officials said.

Doctors will analyze the trial results closely to assess whether GSK can indeed rewrite treatment standards by delivering a cheaper two-drug regimen with fewer side effects.

The worry is it might risk drug resistance because the virus will only have to evade two drugs rather than three. While no resistance was seen in the latest 48-week trials, there was a case in an earlier study, although GSK believes this was likely down to failure to take the drugs properly.

As a result, analysts think many physicians may stick with using three-drug combinations for now, suggesting a slow sales ramp-up for GSK.

That is certainly the expectation at Gilead, which anticipates imminent approval of Biktarvy in Europe and will also have some additional data to present in Amsterdam.

“Physicians are interested in anything new that comes along in HIV, as they should be, but are a bit cautious about anything that steps back from established standards,” Mike Elliott, Gilead’s European head of medical affairs, told Reuters.

GSK is more upbeat but acknowledges the HIV community may be divided.

“Some clinicians will take the 48-week data and be absolutely convinced,” ViiV head of R&D Kimberly Smith told reporters on Wednesday.

“There will be others who, because this is a change in the treatment paradigm, will want to see longer-term data. We will be providing that as the GEMINI studies are designed to go for three years.”

GSK has made HIV a central pillar of the British company’s pharmaceuticals division and its strategy is all about coping with increasingly elderly patients who have to take HIV medicine for decades.

Nearly half of all HIV patients in the profitable markets of North America and Europe are now over 50 and are vulnerable to side effects from the drugs that keep them alive, making tolerability more important than in the past.

“Quality of life is where the unmet medical need is,” said ViiV CEO Waterhouse.

Editing by Alexandra Hudson

The post GSK takes billion-dollar drug fight with Gilead to top AIDS meeting appeared first on World The News.

from World The News https://ift.tt/2teYLT1 via News of World

#Daily World News #Daily Entertainment #Daily Sports #Today News #World The News

0 notes

party-hard-or-die · 6 years